Bellerophon Therapeutics (NASDAQ:BLPH) reported positive top-line data from PHPF-002, a dose escalation, hemodynamics study of INOpulse for the treatment of pulmonary hypertension associated with pulmonary fibrosis.
The top-line results demonstrated that INOpulse, a pulsed nitric oxide treatment, reduced pulmonary vascular resistance and mean pulmonary arterial pressure by 21% and 12%, respectively. Increased benefit on pulmonary resistance was observed on dose escalation to iNO45 from iNO30 (45 and 30 micrograms per kilogram of ideal body weight per hour, respectively).
“The hemodynamic dose response data generated in PHPF-002 validate the pulmonary vasodilatory capability of INOpulse, confirming the therapeutic benefit of iNO30 and supporting further benefit on iNO45,” Fabian Tenenbaum, Bellerophon’s CEO, said in a statement.
“We look forward to further assessing the benefit of INOpulse in our upcoming pivotal Phase 3 study,” he added.